Interleukin-12 targeted to oncofoetal fibronectin
US8420087B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 5, 2005 |
| Grant date | Apr 16, 2013 |
| Priority date | — |
| Expiry date | Jul 5, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterized in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.